Top Stories
NICE clears ITF Pharma's Duvyzat for NHS Duchenne muscular dystrophy use after commercial pricing deal unlocks rejected reimbursement
NICE issued final draft guidance on May 8, 2026 recommending ITF Pharma's Duvyzat (givinostat) for NHS use in England for the treatment of Duchenne muscular dystrophy in patients aged 6 and over who are ambulatory at the start of therapy, following a confidential commercial pricing arrangement that resolved a prior rejection on cost-effectiveness grounds, according to pharmaphorum's coverage of the decision. The agreement, separately confirmed in NICE's own announcement, makes Duvyzat the third NICE-recommended therapy for DMD and is expected to benefit an estimated 530 patients in England. The medicine will be funded through the Innovative Medicines Fund pending final guidance publication, with NHS England required to make the treatment available within 90 days, putting expected patient access around August 2026. Pivotal trial evidence suggests Duvyzat may extend the duration of ambulation by an average of approximately 5 years compared with standard supportive care including corticosteroids — though that estimate carries the uncertainty associated with the natural history modelling used in the NICE submission. The reversal from prior NICE rejection to recommendation following a revised commercial deal reflects a pattern of late-stage HTA negotiation that is increasingly common to rare disease drug access in Europe, with implications for other Duchenne developers preparing UK access submissions.
Intellia Phase 3 HAE data for lonvo-z supports rolling BLA as ATTR editing program resumes screening after prior pause
Intellia Therapeutics disclosed positive topline Phase 3 data from the HAELO trial of lonvo-z, its in vivo CRISPR-based therapy targeting the KLKB1 gene in hereditary angioedema, and has initiated a rolling BLA submission with an anticipated US launch in the first half of 2027, according to Intellia Therapeutics investor relations. HAE affects an estimated 8,000 to 10,000 patients in the United States, a market currently served by prophylactic biologics including Takhzyro and Haegarda as well as Beam Therapeutics and KalVista programs in earlier development stages. Simultaneously, Intellia reported resumption of patient screening in the MAGNITUDE and MAGNITUDE-2 Phase 3 trials evaluating nex-z in ATTR cardiomyopathy and ATTR polyneuropathy, respectively, following a prior screening pause — a development BioPharma Dive has tracked as a key overhang on the ATTR program. The dual-program update positions Intellia as the first company potentially advancing two in vivo CRISPR candidates into or through Phase 3 simultaneously. Regulatory and manufacturing execution risk remains: rolling BLA reviews can extend timelines, and lot-to-lot AAV consistency data will be a focus for FDA reviewers. The ATTR program restart removes a near-term concern but the adequacy of any safety review prompting the original pause warrants continued monitoring.
Lexeo pivotal trial submission for LX2006 in Friedreich ataxia cardiomyopathy advances cardiac AAV gene therapy field ahead of ASGCT readouts
Lexeo Therapeutics submitted the pivotal trial protocol and statistical analysis plan for LX2006, its AAV9-based FXN gene replacement candidate targeting Friedreich ataxia cardiomyopathy, to FDA in Q1 2026 and is awaiting final agency feedback before activating the SUNRISE-FA 2 open-label trial, as reported by Lexeo Therapeutics investor relations. Friedreich ataxia affects approximately 4,000 to 5,000 patients in the United States, with cardiomyopathy representing the leading cause of mortality in this population — a clinical endpoint that carries both regulatory and payer weight. Lexeo also highlighted progress on an Sf9-baculovirus AAV manufacturing platform, which the company plans to present at ASGCT 2026; this system has potential advantages over traditional HEK293 production in scalability and lot consistency, factors that have constrained several cardiac AAV programs. Multiple Lexeo pipeline presentations at ASGCT 2026 are expected to cover the broader cardiac genetic medicine portfolio, per the company's investor update. The FDA feedback on the SUNRISE-FA 2 protocol — particularly on primary endpoints and patient selection criteria — will be a critical determinant of trial feasibility and eventual review pathway, with cardiomyopathy functional endpoints remaining a point of regulatory dialogue across the field.
First FDA-approved therapy for NRG1 fusion-driven cholangiocarcinoma signals regulatory precedent for ultra-rare oncogenic subtypes
Partner Therapeutics received FDA approval for Bizengri, a targeted therapy for cholangiocarcinoma and other solid tumors harboring NRG1 gene fusions, marking the first approved treatment for this molecularly defined ultra-rare cancer subtype, according to MedCity News. NRG1 gene fusions are estimated to occur in fewer than 1% of solid tumors broadly, and the cholangiocarcinoma-specific population is exceptionally small — likely numbering in the low hundreds of annually diagnosed US patients. The approval follows a pattern of FDA willingness to grant accelerated or traditional approval for tumor-agnostic or fusion-defined indications where unmet need is acute and biomarker prevalence is low, as MedCity News reported. For rare disease and gene therapy investors, the precedent is instructive: it reinforces that molecular rarity alone — without large randomized trial infrastructure — can support regulatory action when clinical evidence is coherent. This creates a framework that may be relevant to developers targeting rare genetic driver mutations in hepatic or biliary cancers where gene therapy delivery to the liver is technically feasible. The commercial question — identifying NRG1 fusion patients within an already rare cancer — highlights the diagnostic infrastructure challenge that will define actual addressable volume for this therapy.
Pipeline Watch
The resumption of patient screening in both MAGNITUDE and MAGNITUDE-2 trials of nex-z, Intellia's in vivo CRISPR TTR editing candidate, eliminates a near-term enrollment overhang flagged by investors following the prior pause. ATTR cardiomyopathy alone has an estimated US prevalent population of 100,000 to 150,000, though a portion remains undiagnosed. Competitive pressure from approved TTR silencers Onpattro and Amvuttra and Alnylam's market position means differentiation on durability and single-dose administration will be central to Intellia's commercial thesis, per Intellia Therapeutics investor relations.
The National Cancer Institute launched recruitment for a pediatric, adolescent, and young adult rare cancer registry targeting very rare solid tumors under the Childhood Cancer Data Initiative, per ClinicalTrials.gov. While not a therapeutic trial, this registry infrastructure supports biomarker characterization and patient identification efforts that underpin future gene therapy and molecularly targeted trial design in populations that are typically too small for conventional trial enrollment models.
Competitive Landscape
Intellia lonvo-z in HAE competes with Takeda Takhzyro (lanadelumab) and Pharming Ruconest as well as pipeline CRISPR and gene therapy approaches. In ATTR, nex-z faces Alnylam's entrenched RNAi franchise. Intellia's single-administration positioning is a differentiator but requires durable TTR and KLKB1 suppression data beyond 24 months to meaningfully shift payer and prescriber behavior.
| Program | Modality | Indication | Stage |
|---|---|---|---|
| Intellia lonvo-z | In vivo CRISPR (KLKB1) | HAE | Phase 3 / Rolling BLA |
| Takeda Takhzyro | Biologic (lanadelumab) | HAE | Approved |
| Intellia nex-z | In vivo CRISPR (TTR) | ATTR-CM / ATTRv-PN | Phase 3 Resumed |
| Alnylam Amvuttra | RNAi (vutrisiran) | ATTR-CM / ATTRv-PN | Approved |
Lexeo LX2006 and peers targeting Friedreich ataxia cardiomyopathy face a field where no approved therapy yet addresses the cardiac manifestation directly. Lexeo Sf9-baculovirus manufacturing differentiation, if validated at ASGCT 2026, may create a cost-of-goods and scalability advantage relevant to payer negotiations and commercial pricing models in a roughly 4,000 to 5,000 patient US population.
The Bizengri approval for NRG1-fusion cholangiocarcinoma illustrates a recurring commercial challenge: approvals for molecularly defined ultra-rare indications depend on companion diagnostic availability and oncologist testing behavior. Patient identification lag — not efficacy — may be the primary constraint on commercial uptake, a dynamic relevant to gene therapy developers targeting rare hepatic genetic drivers.
Forward Looking
- The 90-day NHS England implementation clock following NICE's May 8, 2026 final draft guidance puts Duvyzat patient access on track for approximately August 2026; uptake pace, treatment-center readiness, and confirmatory long-term ambulation data will be the near-term watchpoints for ITF Pharma and the broader Duchenne community.
- FDA feedback on the SUNRISE-FA 2 pivotal trial protocol for Lexeo LX2006 — expected in mid-2026 following the Q1 2026 submission — will clarify endpoint requirements and trial activation timeline for Friedreich ataxia cardiomyopathy gene therapy.
- ASGCT 2026 presentations from Lexeo on Sf9-baculovirus AAV manufacturing data will be watched by peer developers and CDMOs tracking alternatives to HEK293 production for high-dose cardiac programs.
- Intellia rolling BLA review for lonvo-z creates a 2026 to 2027 regulatory milestone sequence; completeness determination timing and any clinical hold history on MAGNITUDE will be key investor and payer tracking items.
- The NRG1 fusion cholangiocarcinoma approval sets a template for companion diagnostic co-development requirements in ultra-rare oncology indications with potential implications for rare hepatic gene therapy commercial planning.
🔓 Rare Disease & Gene Therapy Digest • May 4, 2026
Rare Disease & Gene Therapy Digest May 04, 2026 Latus Bio disclosed a $97 million Series A to
View Archive🔓 Rare Disease & Gene Therapy Digest • May 7, 2026
Rare Disease & Gene Therapy Digest May 07, 2026 Angelini Pharma agreed to acquire Catalyst Pharmaceuticals for $4.1
View Archive🔓 Rare Disease & Gene Therapy Digest • April 20, 2026
Rare Disease & Gene Therapy Digest April 20, 2026 Novo Nordisk released Phase 3 data for etavopivat in
View Archive🔓 Rare Disease & Gene Therapy Digest • March 30, 2026
Rare Disease & Gene Therapy Digest March 30, 2026 Two FDA approvals anchor this edition: Rocket Pharmaceuticals received
View Archive🔓 Rare Disease & Gene Therapy Digest • April 9, 2026
Rare Disease & Gene Therapy Digest April 09, 2026 The FDA accepted Ultragenyx's resubmitted BLA seeking accelerated approval
View Archive🔓 Rare Disease & Gene Therapy Digest • March 19, 2026
Rare Disease & Gene Therapy Digest March 19, 2026 The FDA approved Imcivree (setmelanotide) for acquired hypothalamic obesity
View Archive🔓 Rare Disease & Gene Therapy Digest • April 13, 2026
Rare Disease & Gene Therapy Digest April 13, 2026 A thin news week for rare disease clinical data,
View Archive🔓 Rare Disease & Gene Therapy Digest • March 12, 2026
Rare Disease & Gene Therapy Digest March 12, 2026 The FDA lifted Capricor's complete response letter and resumed
View Archive🔓 Rare Disease & Gene Therapy Digest • April 6, 2026
Rare Disease & Gene Therapy Digest April 06, 2026 Neurocrine Biosciences announced a 2.9 billion dollar acquisition of
View Archive🔒 Rare Disease & Gene Therapy Digest • May 11, 2026
Rare Disease & Gene Therapy Digest May 11, 2026 NICE issued final draft guidance on May 8, 2026
Unlock Now🔓 Rare Disease & Gene Therapy Digest • March 23, 2026
Rare Disease & Gene Therapy Digest March 23, 2026 Sarepta Therapeutics disclosed that the FDA has indicated openness
View Archive🔓 Rare Disease & Gene Therapy Digest • April 2, 2026
Rare Disease & Gene Therapy Digest April 02, 2026 The FDA approved label extensions for Vertex Pharmaceuticals ALYFTREK
View Archive🔓 Rare Disease & Gene Therapy Digest • March 26, 2026
Rare Disease & Gene Therapy Digest March 26, 2026 The FDA granted accelerated approval on March 25, 2026
View Archive🔓 Rare Disease & Gene Therapy Digest • March 16, 2026
Rare Disease & Gene Therapy Digest March 16, 2026 BioMarin temporarily halted dosing in two Phase 2 Voxzogo
View Archive🔓 Rare Disease & Gene Therapy Digest • April 27, 2026
Rare Disease & Gene Therapy Digest April 27, 2026 On April 27, 2026, Intellia Therapeutics reported positive Phase
View Archive🔓 Rare Disease & Gene Therapy Digest • April 16, 2026
Rare Disease & Gene Therapy Digest April 16, 2026 Roche announced a new Phase 3 trial for Elevidys
View Archive🔓 Rare Disease & Gene Therapy Digest • April 30, 2026
Rare Disease & Gene Therapy Digest April 30, 2026 Pfizer reached patent settlements extending Vyndamax (tafamidis) exclusivity to
View Archive🔓 Rare Disease & Gene Therapy Digest • April 23, 2026
Rare Disease & Gene Therapy Digest April 23, 2026 On April 23, 2026, the FDA granted accelerated approval
View Archive